61413-70-5

Basic information

• Product Name: Octanoic acid, chloromethyl ester
• Synonyms: octanoyloxymethyl chloride;chloromethyl n-octanoate;Octanoic acid,chloromethyl ester;n-Octanoyloxymethylchloride;3-octanoyloxymethyl chloride
• CAS NO: 61413-70-5
• Molecular Formula: C9H17ClO2
• Molecular Weight: 192.686
• Mol File: 61413-70-5.mol
• Article Data: 19

Chemical Properties

• CAS DataBase Reference: Octanoic acid, chloromethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Octanoic acid, chloromethyl ester(61413-70-5)
• EPA Substance Registry System: Octanoic acid, chloromethyl ester(61413-70-5)

Safety Data

• Hazardous Substances Data: 61413-70-5(Hazardous Substances Data)

Upstream product

• 50-00-0 formaldehyd 
• 124-07-2 Octanoic acid 
• 110-88-3 1,3,5-Trioxan 
• 111-64-8 n-octanoic acid chloride 
• 111-11-5 methyl octanate 
• 3518-65-8 monochloromethanesulfonyl chloride 
• 49715-04-0 chlorosulfuric acid chloromethyl ester 

Relevant articles and documents

PRODRUGS OF CGRP ANTAGONISTS

Disclosed are prodrugs of CGRP antagonists, methods of treating CGRP related disorders, e.g., migraine, by administering to a patient in need thereof the prodrugs, pharmaceutical compositions comprising prodrugs and kits including the pharmaceutical compositions and instructions for use.

Erufosine (ErPC3) Cationic Prodrugs as Dual Gene Delivery Reagents for Combined Antitumor Therapy

Sixteen cationic prodrugs of the antitumor alkylphospholipid (APL) erufosine were rationally synthesized to provide original gene delivery reagents with improved cytotoxicity profile. The DNA complexation properties of these cationic lipids were determined and associated transfection rates were measured. Furthermore, the self-assembly properties of the pro-erufosine compounds were investigated and their critical aggregation concentration was determined. Their hydrolytic stability under pH conditions mimicking the extracellular environment and the late endosome milieu was measured. Hemolytic activity and cytotoxicity of the compounds were investigated. The results obtained in various cell lines demonstrate that the prodrugs of erufosine display antineoplastic activity similar to that of the parent antitumor drug but are not associated with hemolytic toxicity, which is a dose-limiting side effect of APLs and a major obstacle to their use in anticancer therapeutic regimen. Furthermore, by using lipoplexes prepared from a prodrug of erufosine and a plasmid DNA encoding a pro-apoptotic protein (TRAIL), evidence was provided for selective cytotoxicity towards tumor cells while nontumor cells were resistant. This study demonstrates that the combination approach involving well tolerated erufosine cationic prodrugs and cancer gene therapy holds significant promise in tumor therapy.

CONJUGATE-BASED ANTIFUNGAL AND ANTIBACTERIAL PRODRUGS

The invention provides conjugate-based antifungal or antibacterial prodrugs formed by coupling at least one anti-fungal agent or antibacterial agent with at least one linker and/or carrier. The prodrugs are of formula: (i) (AFA)m-X-(L)n; (ii) [(AFA)m′-X]p-L; (iii) AFA-[X-(L)n′]q; or (iv) (AFA)m″-X, wherein: AFA is an antifungal agent or an antibacterial agent; L is a carrier; X is a linker; m ranges from 1 to 10; n ranges from 2 to 10; m′ is 1 to 10; p is 1 to 10; n′ is 1 to 10; and q is 1 to 10, provided that q′ and n are not both 1; and m″ is 1 to 10. The invention also provides nanoparticles comprising the conjugate-based prodrugs. Additionally, the invention also provides non-conjugated antifungal and antibacterial agents in the form of nanoparticles.